A review of interleukin-2 receptor antagonists in solid organ transplantation.
Pharmacotherapy
; 19(10): 1127-37, 1999 Oct.
Article
em En
| MEDLINE
| ID: mdl-10512062
ABSTRACT
Daclizumab and basiliximab, engineered human IgG monoclonal antibodies to the interleukin-2 (IL-2) receptor alpha-subunit, were approved to prevent acute rejection after renal transplantation. Daclizumab was studied in adult and pediatric renal allograft recipients, liver allograft recipients, and calcineurin-sparing protocols in renal transplant recipients. Basiliximab was studied in renal allograft recipients and subgroups of recipients of living-related and cadaveric transplants, and in patients with diabetes mellitus. Both agents reduced acute rejection and were associated with few adverse effects. However, information regarding their long-term effects on infection, malignancy, chronic rejection, and patient survival must be available before a final decision is made regarding their proper administration. We propose that a likely role the drugs will play in the field of solid organ transplantation is in new protocols that allow sparing of other more toxic immunosuppressive agents.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes de Fusão
/
Receptores de Interleucina-2
/
Transplante de Órgãos
/
Rejeição de Enxerto
/
Imunossupressores
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Child, preschool
/
Humans
Idioma:
En
Ano de publicação:
1999
Tipo de documento:
Article